Global Neurology Academy

The Burden of Cognitive Dysfunction in Multiple Sclerosis
The Burden of Cognitive Dysfunction in Multiple Sclerosis
NeuroFrontiers
The Burden of Cognitive Dysfunction in Multiple Sclerosis
- Christopher Lock, MD
Who’s Missing from Multiple Sclerosis Research?
Who’s Missing from Multiple Sclerosis Research?
NeuroFrontiers
Who’s Missing from Multiple Sclerosis Research?
- Ashley Baker, MSN, PMHNP
- Ruth Ann Marrie, MD, PhD
Multiple Sclerosis Without Borders: Taking a Global View
Multiple Sclerosis Without Borders: Taking a Global View
NeuroFrontiers
Multiple Sclerosis Without Borders: Taking a Global View
- Andrew Wilner, MD, FACP, FAAN
- Victor Rivera, MD
Understanding Accelerated Biological Aging in Pediatric MS
Understanding Accelerated Biological Aging in Pediatric MS
NeuroFrontiers
Understanding Accelerated Biological Aging in Pediatric MS
- Jennifer Yang, MD
Advancing MS Care with Multimodal Aging Signatures and Proteomic Biomarkers
Advancing MS Care with Multimodal Aging Signatures and Proteomic Biomarkers
NeuroFrontiers
Advancing MS Care with Multimodal Aging Signatures and Proteomic Biomarkers
- Adil Harroud, MD
- Dylan Hamitouche
- Ryan Quigley
OCEANIC-STROKE Results: Asundexian for Secondary Stroke Prevention After Acute Non-Cardioembolic Stroke or High-Risk TIA
OCEANIC-STROKE Results: Asundexian for Secondary Stroke Prevention After Acute Non-Cardioembolic Stroke or High-Risk TIA
Global Neurology Academy
OCEANIC-STROKE Results: Asundexian for Secondary Stroke Prevention After Acute Non-Cardioembolic Stroke or High-Risk TIA
- Mike Sharma, MD, MSc, FRCPC
Beyond the Primary Endpoint: What OCEANIC-STROKE Subtype Analyses Reveal About Asundexian’s Potential
Beyond the Primary Endpoint: What OCEANIC-STROKE Subtype Analyses Reveal About Asundexian’s Potential
Global Neurology Academy
Beyond the Primary Endpoint: What OCEANIC-STROKE Subtype Analyses Reveal About Asundexian’s Potential
- Ashkan Shoamanesh, MD
Delivering a Hopeful, Recovery-Oriented Schizophrenia Diagnosis
Delivering a Hopeful, Recovery-Oriented Schizophrenia Diagnosis
On the Frontlines of Schizophrenia
Delivering a Hopeful, Recovery-Oriented Schizophrenia Diagnosis
- Alexandria May, PharmD, BCPS
- Apurva Bhatt, MD

Medical News

Medical News
Habitual Activity and Executive Function in Adolescents: Longitudinal Wearable Study
03/11/2026
Read more
Medical News
Sex Differences in Mouse Brain GLP‑1 Mapping: Clinical Implications
03/11/2026
Read more
Medical News
GLP-1 RAs and Substance Use Disorders: Findings from a Veteran Cohort
03/10/2026
Read more
Medical News
EEG Time‑Frequency Images Predict SSRI and rTMS Response
03/10/2026
Read more

See more news

CME/CE

CME/CE In-Person Event
Moving Beyond Sleep: The Broader Connection Between the Orexin System and Psychiatric Disorders
May 27, 2026
May 27, 2026
Miami Beach, Florida
1.00 credit Learn more
Moving Beyond Sleep: The Broader Connection Between the Orexin System and Psychiatric Disorders
Moving Beyond Sleep: The Broader Connection Between the Orexin System and Psychiatric Disorders
CME/CE In-Person Event
Moving Beyond Sleep: The Broader Connection Between the Orexin System and Psychiatric Disorders
May 27, 2026
Miami Beach, Florida
1.00 credit Learn more
New Pathways in the Treatment of DMD
New Pathways in the Treatment of DMD
CME/CE
New Pathways in the Treatment of DMD
1.00 credit
- Erika Finanger, MD, MS
- Aravindhan Veerapandiyan, MD
1.00 credit
Advancing gMG Clinical Decisions: Diagnosing Early, Treating Smarter, and Caring Holistically – A Case-Based Treatment Approach
Advancing gMG Clinical Decisions: Diagnosing Early, Treating Smarter, and Caring Holistically – A Case-Based Treatment Approach
CME/CE
Advancing gMG Clinical Decisions: Diagnosing Early, Treating Smarter, and Caring Holistically – A Case-Based Treatment Approach
0.25 credits
- Christyn Edmundson, MD
- Neelam Goyal, MD
0.25 credits

Clinical Practice

Early ALS Patients Show Slowed Decline with Pridopidine Treatment
Early ALS Patients Show Slowed Decline with Pridopidine Treatment
NeuroFrontiers
Early ALS Patients Show Slowed Decline with Pridopidine Treatment
Rethinking Progression in Multiple Sclerosis
Rethinking Progression in Multiple Sclerosis
NeuroFrontiers
Rethinking Progression in Multiple Sclerosis
- Charles Turck, PharmD, BCPS, BCCCP
- Christopher Lock, MD
GFAP and VEGF Trajectories in Adult Type 3 Spinal Muscular Atrophy Under Nusinersen
GFAP and VEGF Trajectories in Adult Type 3 Spinal Muscular Atrophy Under Nusinersen
NeuroFrontiers
GFAP and VEGF Trajectories in Adult Type 3 Spinal Muscular Atrophy Under Nusinersen
Multiplex Proteomic Biomarkers in MS: Emerging Tools for Precision Care
Multiplex Proteomic Biomarkers in MS: Emerging Tools for Precision Care
NeuroFrontiers
Multiplex Proteomic Biomarkers in MS: Emerging Tools for Precision Care
- Raphael Schneider, MD, PhD, FRCPC, CIP

Programs

Spinal Muscular Atrophy Reveals Hidden Kidney Impairment Risk
Spinal Muscular Atrophy Reveals Hidden Kidney Impairment Risk
NeuroFrontiers
Spinal Muscular Atrophy Reveals Hidden Kidney Impairment Risk
Strategies to Safeguard Brain Health in MS
Strategies to Safeguard Brain Health in MS
NeuroFrontiers
Strategies to Safeguard Brain Health in MS
- Christopher Lock, MD
Switching to Risdiplam Maintains Motor Gains in SMA Patients
Switching to Risdiplam Maintains Motor Gains in SMA Patients
AudioAbstracts
Switching to Risdiplam Maintains Motor Gains in SMA Patients
- Ryan Quigley
Evaluating Structured Interventions for Cognitive Support in MS
Evaluating Structured Interventions for Cognitive Support in MS
AudioAbstracts
Evaluating Structured Interventions for Cognitive Support in MS
- Hallie Blevins, PhD